Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
otherwise, skip the week and resume as scheduled
Danish pharma major Novo Nordisk (NOV: N) presented a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) taking place in Istanbul, Turkey, showing that the higher dose of the weight loss drug Wegovy (semaglutide) Is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment
By reducing the generation of free radicals and enhancing antioxidant defense mechanisms, these agents play a significant role in alleviating oxidative stress, improving metabolic disturbances, and inhibiting inflammatory responses
Further increases to 1 mg or 2 mg weekly may be considered based on glycemic response and tolerability
